cafepharma
@cafepharma.bsky.social
The original site for employees in pharma, medical, and diagnostic sales and related industries. Join us and stay informed.
Wed news: Novo obesity/diabetes US ad spend double’s Lilly’s. Teva expects downturn in 2026. Lilly allies with gene-editing firm on hearing loss. Boehringer’s midstage kidney disease trial momentum. The newest 15 drugs facing IRA pricing cuts. —https://bit.ly/3JeBlY5
January 28, 2026 at 5:09 PM
Wed news: Novo obesity/diabetes US ad spend double’s Lilly’s. Teva expects downturn in 2026. Lilly allies with gene-editing firm on hearing loss. Boehringer’s midstage kidney disease trial momentum. The newest 15 drugs facing IRA pricing cuts. —https://bit.ly/3JeBlY5
Tue news: Roche obesity drug led to 22.5% weight loss in trial. China’s edge in early-stage drugmaking. 5 robotic surgery trends to watch. Boehringer IBD deal. Pfizer retains top spot in physician vaccine rankings. —https://bit.ly/3JeBlY5
January 27, 2026 at 4:41 PM
Tue news: Roche obesity drug led to 22.5% weight loss in trial. China’s edge in early-stage drugmaking. 5 robotic surgery trends to watch. Boehringer IBD deal. Pfizer retains top spot in physician vaccine rankings. —https://bit.ly/3JeBlY5
Mon news: Biopharma layoffs - what’s ahead for 2026. AZ keeps pause on UK R&D site. Express Scripts considering settlement with FTC. Intuitive pushes into cardiac robotic surgery. Merck no longer buying Revolution Medicines. —https://bit.ly/3JeBlY5
January 26, 2026 at 4:56 PM
Mon news: Biopharma layoffs - what’s ahead for 2026. AZ keeps pause on UK R&D site. Express Scripts considering settlement with FTC. Intuitive pushes into cardiac robotic surgery. Merck no longer buying Revolution Medicines. —https://bit.ly/3JeBlY5
Fri news: Sanofi Dupixent successor heads to FDA. Novo’s Wegovy pill launch wows. Big Pharma shops Chinese biotechs for GLP-1s. Bausch’s Xifaxan successor ph III failure. US withdraws from WHO. —https://bit.ly/3JeBlY5
January 23, 2026 at 5:49 PM
Fri news: Sanofi Dupixent successor heads to FDA. Novo’s Wegovy pill launch wows. Big Pharma shops Chinese biotechs for GLP-1s. Bausch’s Xifaxan successor ph III failure. US withdraws from WHO. —https://bit.ly/3JeBlY5
Thurs news: Lexicon opens path to $1B opportunity. Merck and CEPI join forces against Ebola. BMS pens solid tumor pact with Janux. FDA’s Feb 1 PreCheck launch date. Takeda neuro field force layoffs. —https://bit.ly/3JeBlY5
January 22, 2026 at 5:29 PM
Thurs news: Lexicon opens path to $1B opportunity. Merck and CEPI join forces against Ebola. BMS pens solid tumor pact with Janux. FDA’s Feb 1 PreCheck launch date. Takeda neuro field force layoffs. —https://bit.ly/3JeBlY5
Wed news: JNJ earnings. Pfizer CEO lays blame on RFK Jr. Astellas’ banner year. Roche raises NC manufacturing investment. GSK licenses Alteogen enzyme. —https://bit.ly/3JeBlY5
January 21, 2026 at 5:32 PM
Wed news: JNJ earnings. Pfizer CEO lays blame on RFK Jr. Astellas’ banner year. Roche raises NC manufacturing investment. GSK licenses Alteogen enzyme. —https://bit.ly/3JeBlY5
Tue news: GSK buying Rapt for $2.2B for food allergy drug. Trump’s new tariff threats risk upending EU trade deal. Merck-Moderna vaccine sustains melanoma risk reduction. Possible RICO case against Lilly and Takeda. The latest biopharma AI deals. —https://bit.ly/3JeBlY5
January 20, 2026 at 5:02 PM
Tue news: GSK buying Rapt for $2.2B for food allergy drug. Trump’s new tariff threats risk upending EU trade deal. Merck-Moderna vaccine sustains melanoma risk reduction. Possible RICO case against Lilly and Takeda. The latest biopharma AI deals. —https://bit.ly/3JeBlY5
Fri news: Novo’s new Wegovy pill shows solid launch data. JPMHC takeaways. Legal questions swirl around new FDA priority review program. Sanofi rumored to be bidding to takeover Ocular Therapeutix. Trump’s new healthcare proposal and drugmakers. —https://bit.ly/3JeBlY5
January 16, 2026 at 5:13 PM
Fri news: Novo’s new Wegovy pill shows solid launch data. JPMHC takeaways. Legal questions swirl around new FDA priority review program. Sanofi rumored to be bidding to takeover Ocular Therapeutix. Trump’s new healthcare proposal and drugmakers. —https://bit.ly/3JeBlY5
Thurs news: Boston Sci buying Penumbra for $14.5B. JPMHC: Astellas CEO talks Xtandi patent cliff. Lilly, Sanofi among delayed FDA priority reviews. FDA/EMA collab on AI drug development guidelines. JNJ’s case for earlier Tecvayli multiple myeloma use —https://bit.ly/3JeBlY5
January 15, 2026 at 5:03 PM
Thurs news: Boston Sci buying Penumbra for $14.5B. JPMHC: Astellas CEO talks Xtandi patent cliff. Lilly, Sanofi among delayed FDA priority reviews. FDA/EMA collab on AI drug development guidelines. JNJ’s case for earlier Tecvayli multiple myeloma use —https://bit.ly/3JeBlY5
Wed news: JPMHC: AZ’s $80B revenue target within reach. AbbVie, Amgen, Lilly lead calls for updated post-approval change rules. JPMHC: Biotech IPO sector poised to rebound. Travere hammered on surprise FDA delay. Boston Sci gets new PFA catheter approval. —https://bit.ly/3JeBlY5
January 14, 2026 at 5:12 PM
Wed news: JPMHC: AZ’s $80B revenue target within reach. AbbVie, Amgen, Lilly lead calls for updated post-approval change rules. JPMHC: Biotech IPO sector poised to rebound. Travere hammered on surprise FDA delay. Boston Sci gets new PFA catheter approval. —https://bit.ly/3JeBlY5
Tue news: FDA requests removal of suicide warning from GLP-1s. BMS touts pipeline confidence in core pipeline at JPM. JPMHC: Merck sees growth through Keytruda exclusivity loss. Illumina launches dataset to speed up AI drug discovery. Ro and Amgen to study GLP-1 access. —https://bit.ly/3JeBlY5
January 13, 2026 at 5:11 PM
Tue news: FDA requests removal of suicide warning from GLP-1s. BMS touts pipeline confidence in core pipeline at JPM. JPMHC: Merck sees growth through Keytruda exclusivity loss. Illumina launches dataset to speed up AI drug discovery. Ro and Amgen to study GLP-1 access. —https://bit.ly/3JeBlY5
Mon news: Early signals from our AI survey. Reports that Lilly is preparing a bid for Abivax. JPMHC: AbbVie buys RemeGen cancer drug. Novartis makes $1.5B+ cancer play. Nvidia and Eli Lilly are launching an AI drug discovery lab. —https://bit.ly/3JeBlY5
January 12, 2026 at 5:05 PM
Mon news: Early signals from our AI survey. Reports that Lilly is preparing a bid for Abivax. JPMHC: AbbVie buys RemeGen cancer drug. Novartis makes $1.5B+ cancer play. Nvidia and Eli Lilly are launching an AI drug discovery lab. —https://bit.ly/3JeBlY5
Fri news: Why JPM 2026 will mark end of deal drought. Novartis plans new radiopharma plant. Revolution Med soars amid swirling buyout rumors. Amazon Pharmacy to offer Wegovy pill. JNJ strikes drug pricing deal with federal government. —https://bit.ly/3JeBlY5
January 9, 2026 at 4:57 PM
Fri news: Why JPM 2026 will mark end of deal drought. Novartis plans new radiopharma plant. Revolution Med soars amid swirling buyout rumors. Amazon Pharmacy to offer Wegovy pill. JNJ strikes drug pricing deal with federal government. —https://bit.ly/3JeBlY5
We’re running a short, anonymous survey to better understand how those in the industry are using AI today. Results will be shared at a high level with the community. Please let us know your thoughts here: forms.gle/8xPdatew4hDh...
2026 AI Survey
Cafepharma is conducting a short, anonymous survey to better understand how people working in pharma sales, medical sales, and adjacent industries are using AI tools today, what concerns they have, an...
forms.gle
January 9, 2026 at 2:45 PM
We’re running a short, anonymous survey to better understand how those in the industry are using AI today. Results will be shared at a high level with the community. Please let us know your thoughts here: forms.gle/8xPdatew4hDh...
Thurs news: Layoffs up 47% year over year. Drugmakers brace for Europe pricing fight. AZ names new US biopharma head. Court blocks HHS' 340B rebate program pilot. Lilly is buying Ventyx. —https://bit.ly/3JeBlY5
January 8, 2026 at 4:58 PM
Thurs news: Layoffs up 47% year over year. Drugmakers brace for Europe pricing fight. AZ names new US biopharma head. Court blocks HHS' 340B rebate program pilot. Lilly is buying Ventyx. —https://bit.ly/3JeBlY5
Wed news: Lilly’s prospective CV launches dominate Clarivate list. 5 drug approvals to watch in 2026. Lilly might be looking to buy Ventyx Bio. GSK hep B treatment proves worth in phase 3. Amgen-Disco $618M cancer pact. —https://bit.ly/3JeBlY5
January 7, 2026 at 5:12 PM
Wed news: Lilly’s prospective CV launches dominate Clarivate list. 5 drug approvals to watch in 2026. Lilly might be looking to buy Ventyx Bio. GSK hep B treatment proves worth in phase 3. Amgen-Disco $618M cancer pact. —https://bit.ly/3JeBlY5
Tue news: Amgen buying protein-degrading startup. Why Sanofi got an FDA rejection for its MS drug. CDC drops some vaccines from pediatric schedule. Lilly taps Nimbus for another obesity candidate. Boehringer continues kidney disease dealmaking run. —https://bit.ly/3JeBlY5
January 6, 2026 at 5:09 PM
Tue news: Amgen buying protein-degrading startup. Why Sanofi got an FDA rejection for its MS drug. CDC drops some vaccines from pediatric schedule. Lilly taps Nimbus for another obesity candidate. Boehringer continues kidney disease dealmaking run. —https://bit.ly/3JeBlY5
Mon news: Novo launches first GLP-1 obesity pill in the US. Insilico and Servier in $888M oncology pact. Moderna seeks global flu vaccine approvals. Incyte’s blood cancer therapy succeeds in late stage trial. Novo leadership shakeup. —https://bit.ly/3JeBlY5
January 5, 2026 at 5:26 PM
Mon news: Novo launches first GLP-1 obesity pill in the US. Insilico and Servier in $888M oncology pact. Moderna seeks global flu vaccine approvals. Incyte’s blood cancer therapy succeeds in late stage trial. Novo leadership shakeup. —https://bit.ly/3JeBlY5
Fri news: Pfizer leads industry drug price surge. Novo gets semaglutide IP win in China. 2025’s largest med tech funding rounds. Biohaven flunks phase 2 depression trial. AbbVie doubles down on trispecifics. —https://bit.ly/3JeBlY5
January 2, 2026 at 4:21 PM
Fri news: Pfizer leads industry drug price surge. Novo gets semaglutide IP win in China. 2025’s largest med tech funding rounds. Biohaven flunks phase 2 depression trial. AbbVie doubles down on trispecifics. —https://bit.ly/3JeBlY5
Mon news: 9 pharma cos reach US drug price deal with White House. AZ’s ATR inhibitor fails to improve survival in lung cancer trial. Battle sets up between Cytokinetics and BMS. Biopharma CEO optimism wavering. Radiopharmaceutical IPO. —https://bit.ly/3JeBlY5
December 22, 2025 at 5:16 PM
Mon news: 9 pharma cos reach US drug price deal with White House. AZ’s ATR inhibitor fails to improve survival in lung cancer trial. Battle sets up between Cytokinetics and BMS. Biopharma CEO optimism wavering. Radiopharmaceutical IPO. —https://bit.ly/3JeBlY5
Fri news: Biomarin buying rare disease drugmaker Amicus. Boehringer walks away from schizophrenia program. Alvotech and Teva eye 2026 Eylea biosim launch. Biogen betting on a tech and AI overhaul. BioSecure Act passes Congress. —https://bit.ly/3JeBlY5
December 19, 2025 at 6:00 PM
Fri news: Biomarin buying rare disease drugmaker Amicus. Boehringer walks away from schizophrenia program. Alvotech and Teva eye 2026 Eylea biosim launch. Biogen betting on a tech and AI overhaul. BioSecure Act passes Congress. —https://bit.ly/3JeBlY5
Thurs news: FDA mulls national priority vouchers for 2 potential Merck blockbusters. Novo submits NDA to FDA for CagriSema. Takeda plans psoriasis filing. Moderna scores $54M From CEPI. AbbVie and others near MFN deal. —https://bit.ly/3JeBlY5
December 18, 2025 at 5:31 PM
Thurs news: FDA mulls national priority vouchers for 2 potential Merck blockbusters. Novo submits NDA to FDA for CagriSema. Takeda plans psoriasis filing. Moderna scores $54M From CEPI. AbbVie and others near MFN deal. —https://bit.ly/3JeBlY5
Wed news: 6 biotechs that could be Big Pharma’s next M&A target. BMS and Harbour BioMed sign multi-specific antibody collab. Medline set for debut after 2025’s biggest IPO. Padcev-Keytruda scores in early bladder cancer. GSK’s asthma approval. —https://bit.ly/3JeBlY5
December 17, 2025 at 4:29 PM
Wed news: 6 biotechs that could be Big Pharma’s next M&A target. BMS and Harbour BioMed sign multi-specific antibody collab. Medline set for debut after 2025’s biggest IPO. Padcev-Keytruda scores in early bladder cancer. GSK’s asthma approval. —https://bit.ly/3JeBlY5
Tue news: Pfizer foresees challenging 2026. Genentech and Caris in $1.1B deal for rare cancer targets. Pfizer and Sanofi in separate autoimmune pacts. Makary says no black box on COVID vaccines. AZ-Daiichi get FDA nod in first line breast cancer —https://bit.ly/3JeBlY5
December 16, 2025 at 5:16 PM
Tue news: Pfizer foresees challenging 2026. Genentech and Caris in $1.1B deal for rare cancer targets. Pfizer and Sanofi in separate autoimmune pacts. Makary says no black box on COVID vaccines. AZ-Daiichi get FDA nod in first line breast cancer —https://bit.ly/3JeBlY5
Mon news: Sanofi suffers double setback for MS drug. Philips adding AI heart imaging with company purchase. Gilead HIV trial results. Pfizer’s $890M deal with Adaptive Biotech. BioSecure Act may be finally headed to Trump’s desk —https://bit.ly/3JeBlY5
December 15, 2025 at 5:06 PM
Mon news: Sanofi suffers double setback for MS drug. Philips adding AI heart imaging with company purchase. Gilead HIV trial results. Pfizer’s $890M deal with Adaptive Biotech. BioSecure Act may be finally headed to Trump’s desk —https://bit.ly/3JeBlY5